甲状腺癌组织的CCL11、VEGF表达与病理特征的关系

doi:10.3760/cma.j.issn.1007-1245.2023.18.012

摘要/Abstract

摘要：

目的　探讨甲状腺癌组织的嗜酸性粒细胞趋化因子（CC chemokine ligand 11，CCL11）、血管内皮生长因子（vascular endothelial growth factor，VEGF）表达与病理特征的关系。方法　采集2020年12月至2022年12月在青岛滨海学院附属医院收集的120例甲状腺癌组织病理标本及同期收集的60例正常甲状腺组织标本进行回顾性研究。将120例甲状腺癌组织病理标本设为观察组，男42例，女78例，年龄25～87（54.58±5.36）岁；将60例甲状腺良性疾病组织标本设为对照组，男21例，女39例，年龄26～86（53.66±5.65）岁。两组均采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结法（streptavidin-peroxidase method，SP）检测其CCL11、VEGF表达阳性率，并分析CCL11、VEGF与甲状腺癌病理特征的关系。采用χ²检验。结果　与对照组比较，观察组的CCL11［95.00%（114/120）］、VEGF［80.00%（96/120）］阳性表达率明显更高（χ²=64.685、33.264，均P<0.05）。甲状腺组织TNM分期为Ⅲ+Ⅳ期［100.00%（48/48）］、有淋巴结转移［100.00%（48/48）］、浸润深度为T3+T4［98.68%（75/76）］的患者CCL11阳性表达率明显高于TNM分期为Ⅰ+Ⅱ期［91.67%（66/72）］、无淋巴结转移［91.67%（66/72）］、浸润深度为T1+T2［88.64%（39/44）］的患者（χ²=4.211、4.211、5.923，均P<0.05）。甲状腺组织低分化［96.43%（27/28）］、TNM分期为Ⅲ+Ⅳ期［95.83%（46/48）］、有淋巴结转移［91.67%（44/48）］、浸润深度为T3+T4［94.74%（72/76）］、有复发或转移［95.56%（43/45）］的患者VEGF阳性表达率明显高于高+中分化［75.00%（69/92）］、TNM分期为Ⅰ+Ⅱ期［69.44%（50/72）］、无淋巴结转移［72.22%（52/72）］、浸润深度为T1+T2［54.55%（24/44）］、无复发或转移［70.67%（53/75）］的患者（χ²=6.161、12.535、6.806、28.134、10.889，均P<0.05）。甲状腺癌组织CCL11阳性表达与TNM分期、淋巴结转移、浸润深度呈正相关（均P<0.05）；甲状腺癌组织VEGF阳性表达与分化程度、TNM分期、淋巴结转移、浸润深度、复发或转移呈正相关（均P<0.05）。结论　甲状腺癌组织的CCL11、VEGF阳性表达与其TNM分期、淋巴结转移、浸润深度等病理特征存在一定关联。检测CCL11、VEGF的表达可有效评估患者疾病严重程度，为后续治疗提供科学的参考依据。

关键词:

甲状腺癌组织, CCL11, VEGF, 阳性表达, 病理特征, 相关性

Abstract:

Objective　To investigate the relationship between the expressions of CC chemokine ligand 11 (CCL11) and vascular endothelial growth factor (VEGF) in thyroid carcinoma and pathological features. Methods　One hundred and twenty thyroid cancer tissue pathological specimens collected from Hospital Affiliated to Qingdao Binhai University from December 2020 to December 2022 and 60 benign thyroid disease tissue specimens collected during the same period were retrospectively analyzed. The 120 thyroid cancer tissue pathological specimens were set as an observation group, including 42 males and 78 females who were 25-87 (54.58±5.36) years old. The 60 benign thyroid disease tissue specimens were set as a control group, including 21 males and 39 females who were 26-86 years old. The immunohistochemical streptavidin-peroxidase (SP) method was used to detect the positive expression rates of CCL11 and VEGF. The relationship between CCL11 and VEGF on one hand and the pathological characteristics of thyroid cancer on the other hand was analyzed. χ² test was applied. Results　Compared with those in the control group, the positive expression rates of CCL11 [95.00% (114/120)] and VEGF [80.00% (96/120)] in the observation group were significantly higher (χ²=64.685 and 33.264; both P<0.05). The positive expression rates of CCL11 in the patients with Ⅲ + Ⅳ TNM stages [100.00% (48/48)], lymph node metastasis [100.00% (48/48)], and T3 + T4 depths of invasion [98.68% (75/76)] were significantly higher than those in the patients with I + Ⅱ TNM stages [91.67% (66/72)], no lymph node metastasis [91.67% (66/72)], and T1 + T2 depths of invasion [88.64% (39/44)] (χ²=4.211, 4.211, and 5.923; all P<0.05). The positive expression rates of VEGF in the patients with poorly differentiated thyroid tissue [96.43% (27/28)], Ⅲ + Ⅳ TNM stages [95.83% (46/48)], lymph node metastasis [91.67% (44/48)], T3 + T4 depths of invasion [94.74% (72/76)], and recurrence or metastasis [95.56% (43/45)] were significantly higher than those in the patients with high + moderate differentiation [75.00% (69/92)], I + Ⅱ TNM stages [69.44% (50/72)], no lymph node metastasis [72.22% (52/72)], T1 + T2 depths of invasion [54.55% (24/44)], and no recurrence or metastasis [70.67% (53/75)] (χ²=6.161, 12.535, 6.806, 28.134, and 10.889; all P<0.05). The positive expression of CCL11 in thyroid cancer tissue was positively correlated with TNM stage, lymph node metastasis, and depth of invasion (all P<0.05). The positive expression of VEGF in thyroid carcinoma was positively correlated with the degree of differentiation, TNM stage, lymph node metastasis, depth of invasion, and recurrence or metastasis (all P<0.05). Conclusions　The positive expressions of CCL11 and VEGF in thyroid cancer tissue are related to pathological features, such as TNM stage, lymph node metastasis, and depth of invasion. By detecting the expression of CCL11 and VEGF, the disease severity can be effectively evaluated, so as to provide scientific references for subsequent treatment.

Key words:

Thyroid cancer tissue, CCL11, VEGF, Positive expression, Pathological features, Correlation

张红红李涌.

甲状腺癌组织的CCL11、VEGF表达与病理特征的关系 [J]. 国际医药卫生导报, 2023, 29(18): 2566-2570.

Zhang Honghong, Li Yong.

Relationship between expressions of CCL11 and VEGF in thyroid carcinoma and pathological features [J]. International Medicine and Health Guidance News, 2023, 29(18): 2566-2570.

参考文献

[1] 赵洁,黄美玲,凌瑞,等. 儿童及青少年甲状腺癌的临床病理特点及BRAFV600E突变[J]. 现代肿瘤医学,2020,28(7):1120-1124. DOI:10.3969/j.issn.1672-4992.2020.07.014.
[2] 李昌盛,郜建姣. 完全腔镜下甲状腺手术治疗分化型甲状腺癌的疗效及对相关因子的影响[J]. 癌症进展,2019,17(13):1569-1572. DOI:10.11877/j.issn.1672-1535.2019. 17.13.23.
[3] 方芳,韩路,方开峰. 超声参数联合血清VEGF、IL-17、sIL-2R对甲状腺癌的诊断效能及与病理特征的关联[J]. 中国临床研究,2020,33(8):1027-1031. DOI:10.13429/j.cnki.cjcr.2020.08.005.
[4] 陈天宇,秦少云,姜克家,等. 肺鳞状细胞癌血清 CCL11表达及临床意义研究[J]. 临床和实验医学杂志,2016,15(21):2107-2110. DOI:10.3969/j.issn.1671-4695.2016.21.012.
[5] Baloch ZW, Asa SL, Barletta JA, 等.2022年WHO甲状腺肿瘤分类概述[J].诊断病理学杂志, 2022, 29(12): 1193.
[6] 曲衍清,刘新强,崔莎莎,等. 甲状腺癌组织中环氧合酶-2、CD163和血管内皮生长因子的表达及临床意义[J]. 中华生物医学工程杂志,2021,27(5):528-532. DOI:10.3760/cma.j.cn115668-20210622-00150.
[7] 吴洁清,王海峰,寇小格. VEGF-B、白细胞介素-6和B淋巴细胞瘤-2在甲状腺癌中的诊断价值[J]. 广东医学,2019,40(6):861-863,867. DOI:10.13820/j.cnki.gdyx.20182226.
[8] 徐林霞,王素萍,徐国霞,等. 超声弹性成像参数联合血清MK和VEGF对分化型甲状腺癌的诊断价值及与肿瘤恶性程度关系研究[J]. 影像科学与光化学,2021,39(1):12-18. DOI:10.7517/issn.1674-0475.200609.
[9] 白亚楠,朱德苑,刘元奎,等. 治疗前血清Tg、TgAb、VEGF、MIP-1α对分化型甲状腺癌术后患者首次131碘清甲治疗效果的影响[J]. 现代生物医学进展,2023,23(2):361-366. DOI:10.13241/j.cnki.pmb.2023.02.030.
[10] 孔桂莲,孙永敏,张振华,等. 血清血管内皮生长因子诊断乳头状甲状腺癌的价值[J]. 中华实用诊断与治疗杂志,2020,34(7):693-695. DOI:10.13507/j.issn.1674-3474. 2020.07.012.
[11] 臧荣发,顾盼瑾,尤建良. 联合检测血清galectin-3、sIL-2R、CCL11表达水平在评估结肠癌患者预后中的价值研究[J]. 河北医药,2019,41(10):1460-1463,1468. DOI:10.3969/j.issn.1002-7386.2019.10.004.
[12] 左华,周冬,陈晓军. 血清CCL11、GPX3和Gal-1水平在分化型甲状腺癌诊断中的临床价值[J]. 检验医学与临床,2022,19(5):586-590. DOI:10.3969/j.issn.1672-9455. 2022.05.003.
[13] 毕日军,郗彦凤. 乳头状甲状腺癌中表皮生长因子受体和黏附斑激酶表达及其临床意义[J]. 标记免疫分析与临床,2019,26(7):1113-1116,1144. DOI:10.11748/bjmy.issn.1006-1703.2019.07.008.
[14] Coperchini F, Croce L, Marinò M, et al. Role of chemokine receptors in thyroid cancer and immunotherapy[J]. Endocr Relat Cancer, 2019, 26(8): R465-R478.
[15] 陈宏月,李兴江. 甲状腺全切除术对甲状腺癌患者血清血管内皮生长因子、可溶性Fas受体、可溶性Fas受体配体mRNA表达的影响研究[J]. 陕西医学杂志,2020,49(1):96-98,108. DOI:10.3969/j.issn.1000-7377.2020.01.026.
[16] Vela-Gaxha Z, Shahini L, Manxhuka-Kerliu S. The prognostic role of vascular endothelial growth factor-A expression in thyroid carcinomas [J]. Folia Med (Plovdiv), 2019, 61(1):61-68. DOI: 10.2478/folmed-2018-0059.
[17] 李国胜,王红岩,赵晓丹,等. IGF-1、Twist2、VEGF在胃癌组织中的表达及临床意义[J]. 解放军医药杂志,2019,31(1):9-11. DOI:10.3969/j.issn.2095-140X.2019.01.003.
[18] 林媛,笪茂红,乔伟,等. 超声检查参数联合血清VEGF、Tg、Gal-1对甲状腺癌的诊断价值及其与淋巴结转移的关系[J]. 现代生物医学进展,2022,22(15):2976-2980. DOI:10.13241/j.cnki.pmb.2022.15.034.
[19] 王珊珊,戚建国,王洲,等. 超声联合血清VEGF、TSGF检查对分化型甲状腺癌的诊断价值及与临床病理特征的相关性[J]. 川北医学院学报,2022,37(4):437-441. DOI:10.3969/j.issn.1005-3697.2022.04.007.
[20] 邢怀广,王鲁卿,李娟,等. 甲状腺癌术后复发/转移患者血清VEGF、ES的表达水平[J]. 标记免疫分析与临床, 2022, 29(9): 1542-1544, 1572. DOI: 10.11748/bjmy.issn. 1006-1703.2022.09.023.